DaVita stock (US23918K1088): TD Cowen raises price target to $201

TD Cowen raised its price target on DaVita from $144 to $201 on May 11, 2026, amid a wave of bullish analyst updates from Barclays, Deutsche Bank, UBS and Truist.

DaVita stock saw fresh analyst attention as TD Cowen increased its price target from $144 to $201 in a research note issued on Monday, May 11, 2026, according to MarketBeat as of May 11, 2026. This move reflects growing optimism, with the new target implying minimal downside from recent trading levels around $201. Other firms have similarly upgraded views, including Deutsche Bank lifting to $220 with a buy rating on May 6.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: DaVita Inc.
• Sector/industry: Healthcare / Dialysis Services
• Headquarters/country: United States
• Core markets: US dialysis centers
• Key revenue drivers: Kidney care services
• Home exchange/listing venue: NYSE (DVA)
• Trading currency: USD

DaVita: core business model

DaVita Inc. operates as a leading provider of kidney care services in the United States, managing a network of dialysis centers that treat patients with chronic kidney failure. The company serves approximately 200,000 patients annually through over 2,700 outpatient dialysis centers, according to its investor relations materials. This model focuses on integrated care, including home dialysis and transplant support, generating stable revenue from government and private payers.

DaVita's operations emphasize operational efficiency and patient outcomes, with a significant portion of revenue tied to Medicare reimbursements. The firm has expanded into ancillary services like pharmacy and transplant logistics, diversifying beyond traditional in-center dialysis. For US investors, DaVita offers exposure to the growing end-stage renal disease market, driven by aging demographics and diabetes prevalence.

Main revenue and product drivers for DaVita

DaVita's primary revenue comes from dialysis treatments, accounting for the bulk of its top line, supplemented by lab services and international operations. In recent quarters, US dialysis has remained the core driver, with patient volume growth supporting topline expansion despite reimbursement pressures. The stock traded at $198.93 on NYSE on May 11, 2026, up 0.14% for the day, per StockInvest.us as of May 11, 2026.

Key products include in-center hemodialysis, peritoneal dialysis and home therapies, with ancillary revenue from medications and diagnostics. DaVita's share repurchase program has been aggressive, leading Goldman Sachs' Buyback Aristocrats Index by reducing share count 9% annually, as noted in GuruFocus reporting.

Industry trends and competitive position

The US dialysis sector faces steady demand from rising chronic kidney disease cases, projected to grow with the population over 65. DaVita holds a dominant position alongside Fresenius Medical Care, commanding over 70% market share in outpatient dialysis. Regulatory changes on reimbursements pose challenges, but DaVita's scale enables cost controls and innovation in value-based care models relevant to US healthcare spending.

Why DaVita matters for US investors

Listed on NYSE, DaVita provides direct exposure to America's healthcare system, where kidney care represents a $50 billion annual market. Its recession-resistant model, backed by essential services, appeals to portfolios seeking defensive healthcare plays amid economic cycles. Recent stock gains of 31% in one week as of early May 2026 underscore momentum, per Zacks as of recent publication.

DaVita stock price trends

DaVita shares have shown strong momentum, rising 30.99% in a recent week and 33.37% over the past quarter. The stock moved from $198.65 to $198.93 on May 11, 2026, on NYSE. Insider activity included CFO Joel Ackerman selling 51,471 shares at $192.099 average on May 7, 2026, per SEC Form 4 filings.

Conclusion

DaVita continues to draw analyst upgrades, with TD Cowen and peers signaling confidence in its kidney care leadership. Share buybacks and market momentum support the NYSE-listed stock's appeal for US investors tracking healthcare. Ongoing insider sales and regulatory dynamics warrant monitoring as the company navigates sector trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.